In-depth coverage of the UK’s exit from the EU, and what it means to pharma and healthcare.
Health and business secretaries commit to close working with EMA
How the UK’s exit from the EU may influence pharma companies’ decisions to stay or go.
Saratha Rajeswaran will lead government affairs team
New cost-capping and delaying measures will further restrict access to new medicines say pharma and patient groups.
March 14, 2017
Significant unmet need still remains in the rare disease market, only around 5% of rare diseases currently have an approved drug treatment. This represents a major opportunity for the pharmaceutical industry. Our webinar will assess the critical factors underpinning success in the rare disease space and provide a view into the future of market access and health technology assessments for orphan medicines – alongside the impact on R&D and clinical trials – in the context of Brexit negotiations.
Experts call for shake-up of EU regulation.
Peers introduce amendment to Brexit bill.
Britain will be in “second or third tier” of drug launches, experts warn.
UK pharma leaders are putting a brave face on Brexit – but the ‘phoney war’ is about to give way to hard-nosed negotiations
But longer-term benefits could include faster reimbursement decisions.